Currently, Indonesia is experiencing a dramatic demographic shift caused by the explosion of the elderly population, or people aged 60 years and older. In 2017, Special Region of Yogyakarta was the province with the highest elderly population in Indonesia. The increase of the elderly population requires action from all parties in anticipating various problems related to the elderly, especially elderly women, including their reproductive health, mental health, and change of nutrition needed. The peri and postmenopausal period constitutes a challenging transition time for women’s health, and menopausal health is a crucial aspect in healthy and successful aging. Sleman Regency Government has implemented community-based health service or elderly integrated service post. Health care volunteers (cadres) play an essential role in carrying out the objectives of an elderly integrated service post. Therefore, it requires knowledge and skills enhancement of the cadres about elderly women’s health. Training that included lectures and discussion could improve the knowledge and skills of women elderly health cadres, provide the optimal quality of health service in elderly integrated service post, and increase public awareness about the importance of health services in providing health information for the women elderly.
Background Pelvic organ prolapse (POP) is a prevalent condition caused by weakened pelvic floor support structures. Extracellular matrix alterations, including changes in collagen type I, collagen type III, and matrix metalloproteinase 1 (MMP-1), contribute to the pathogenesis of this condition. Human platelet-rich fibrin lysate (hPRF-L) is a novel regenerative treatment that has shown beneficial results in treating structural weaknesses related to various pelvic floor diseases, including POP. Methods This study protocol aims to investigate the effects of hPRF-L injection on collagen I, III, and MMP-1 in the vaginal mucosa of a rat POP model. POP will be induced in female Sprague-Dawley rats, which will be randomly assigned to control, sham, and hPRF-L treatment groups. The hPRF-L group will receive weekly injections of hPRF-L (25, 50, or 75 μL) into the vaginal mucosa for 4 weeks. Vaginal tissue samples will be collected, and collagen type I, collagen type III, and MMP-1 expression will be evaluated using quantitative reverse transcription polymerase chain reaction and immunohistochemical analyses. Data analysis will be performed with ANOVA and post-hoc tests. Discussion The findings from this study protocol are expected to provide valuable insights into the mechanisms by which hPRF-L impacts the structural integrity of the pelvic floor. By elucidating these mechanisms, this study aims to inform future POP treatment strategies. The anticipated results are an increase in collagen type I and III expression and a reduction in MMP-1 levels in the hPRF-L treatment group compared to the control and sham groups. These outcomes could support the use of hPRF-L as a regenerative therapy for managing POP, offering a potential alternative to more invasive surgical interventions. Conclusion The expected results will contribute to the development of less invasive treatments for POP, improving patient outcomes and quality of life.
13 May 2024 in Case Reports in Obstetrics and Gynecology
Intrauterine contraceptive devices (IUCD) are widely used as a reversible method of contraception. Although uterine perforation caused by an IUCD is rare, in some cases, the device may migrate to the pelvic/abdominal cavity or nearby structures. When the IUCD migrate to the bladder, it can lead to various symptoms. These include pain or discomfort in the lower abdomen, difficulties or pain during urination, frequent urinary tract infections, and the development of bladder stones. This article presents a case report of a 24-year-old woman with an intrauterine contraceptive device (IUCD) that had migrated completely into the bladder. She had an IUCD inserted by a midwife four years earlier and became pregnant a year later, unaware of the IUCD’s presence. She later presented with lower abdominal pain, hematuria, and dysuria three months before being admitted to our hospital. Imaging confirmed the intravesical location of the IUCD. She underwent successful cystoscopy treatment to remove the migrated IUCD. Prompt diagnosis and appropriate management are crucial in preventing complications and improving patient outcomes. Clinicians should be aware of this potential complication and consider it when patients present with symptoms or complications after IUCD insertion. Regular monitoring and timely intervention can help detect and address IUCD migration effectively.
Background : Platelet-rich plasma (PRP) is an autologous, self-blood product, anticoagulated blood product generated by centrifugation method of whole blood that primarily contains platelets at amounts up to 5 times those found in physiologic platelet concentrations. PRP contains multiple growth factors such as transforming growth factor (TGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and insulin-like growth factor-1 within the alpha granules of platelets (IGF-1). Platelets also contain antibacterial and fungicidal proteins, metalloproteinases, coagulation factors, and membrane glycoproteins, which can regulate inflammation by promoting the production of various integrins, interleukins, and chemokines. Pelvic organ prolapse occurs when the genitalia organ, bladder, rectum, and intestine protrude into the vaginal canal or even out of it due to the weakening of ligaments and muscles that serve as suspensors for the pelvic organs. Surgery is one of the treatment options for pelvic organ prolapse. The use of platelet rich plasma in pelvic organ prolapse surgery is becoming much more common. The goal of this procedure is to reconstruct the anatomical components of the pelvic supporting tissues and increase the healing process. To determine the efficacy of PRP on pelvic organ prolapse surgery, we will synthesize the available research on the use of platelet rich plasma for pelvic organ prolapse surgery. The goal of this study is to conduct a scoping study of the published research on the efficacy of platelet rich plasma for the surgery procedure of female pelvic organ prolapse. Methods/design : This review was conducted on research articles in PubMed, Proquest, EBSCO, ScienceDirect databases published between January 2010 – Desember 2021 regarding the use of platelet rich plasma for pelvic organ prolapse surgery. All primary research in human, case reports and case series will be included to evaluate the outcome of platelet rich plasma as an adjunct to conventional surgery in the treatment of pelvic organ prolapse. Discussion : This review will offer actual evidence of PRP's efficacy for pelvic organ prolapse surgery. This is a new approach, and the findings of this study are expected to inform clinical practice and ongoing research focused on improving outcome of pelvic organ prolapse surgery. Trial registration number : osf.io/gyr72